MYTESI Drug Patent Profile

Which patents cover Mytesi, and when can generic versions of Mytesi launch?

Mytesi is a drug marketed by Napo Pharms Inc and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-eight patent family members in twenty-two countries.

The generic ingredient in MYTESI is crofelemer. One supplier is listed for this compound. Additional details are available on the crofelemer profile page.

DrugPatentWatch^® Generic Entry Outlook for Mytesi

Mytesi was eligible for patent challenges on December 31, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 31, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for MYTESI

International Patents:	28
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Drug Prices:	Drug price information for MYTESI
What excipients (inactive ingredients) are in MYTESI?	MYTESI excipients list
DailyMed Link:	MYTESI at DailyMed

See drug prices for MYTESI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MYTESI

NDA:

202292

Dosage:

TABLET, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MYTESI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Beth Israel Deaconess Medical Center	Phase 4
Napo Pharmaceuticals, Inc.	Phase 4

See all MYTESI clinical trials

Pharmacology for MYTESI

Drug Class

Antidiarrheal

US Patents and Regulatory Information for MYTESI

MYTESI is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Napo Pharms Inc	MYTESI	crofelemer	TABLET, DELAYED RELEASE;ORAL	202292-001	Dec 31, 2012		RX	Yes	Yes
Napo Pharms Inc	MYTESI	crofelemer	TABLET, DELAYED RELEASE;ORAL	202292-001	Dec 31, 2012		RX	Yes	Yes

Expired US Patents for MYTESI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Napo Pharms Inc	MYTESI	crofelemer	TABLET, DELAYED RELEASE;ORAL	202292-001	Dec 31, 2012
Napo Pharms Inc	MYTESI	crofelemer	TABLET, DELAYED RELEASE;ORAL	202292-001	Dec 31, 2012
Napo Pharms Inc	MYTESI	crofelemer	TABLET, DELAYED RELEASE;ORAL	202292-001	Dec 31, 2012

International Patents for MYTESI

When does loss-of-exclusivity occur for MYTESI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Colombia

Denmark

Ecuador

European Patent Office

Hong Kong

Hungary

Japan

Malaysia

Mexico

Peru

Poland

Portugal

Russian Federation

South Africa

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MYTESI around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	201303136	METHODS AND COMPOSITION FOR TREATING HIV-ASSOCIATED DIARRHEA
Colombia	6771411
Ukraine	109159	СПОСОБИ І КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ ВІЛ-АСОЦІЙОВАНОЇ ДІАРЕЇ
South Korea	20000049206
Spain	2635435
Russian Federation	2597746	СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ВИЧ-АССОЦИИРОВАННОЙ ДИАРЕИ (METHODS AND COMPOSITIONS FOR TREATING HIV-ASSOCIATED DIARRHOEA)

Last updated: April 24, 2026

MYTESI (Crofelemer) Market Dynamics and Financial Trajectory

MYTESI (crofelemer) is an oral, plant-derived proprietary drug with a narrow label footprint built around gastrointestinal indications. Market dynamics for MYTESI are driven by (1) clinician adoption in targeted patient segments, (2) payer access and contracting versus low-cost alternatives, (3) the cadence of post-approval evidence updates and label expansion efforts, and (4) the company’s ability to fund commercialization and inventory through cash flows. Financial trajectory is dominated by commercialization scale, gross-to-net dynamics, and ongoing operating cost control rather than by blockbuster-like sales volume.

What is the core market position of MYTESI?

MYTESI is marketed as crofelemer for symptom management in adults with noninfectious diarrhea and is sold in the US under the brand MYTESI by Napo Pharmaceuticals. Commercialization in GI remains competitive because many prescribers treat chronic diarrhea symptomatically and can switch quickly when payer coverage changes or when low-cost options are preferred.

Key structural forces shaping demand:

• Indication specificity: adoption concentrates among gastroenterology and GI-heavy practices rather than general primary care.
• Payer friction: GI symptom therapies face step edits, prior authorization, and copay pressure. Formulary position is often decisive for script volume.
• Therapy switching costs are low: symptom control products can lose share if coverage deteriorates or if perceived efficacy differentiation narrows.

How do payer and channel economics affect MYTESI sales?

For niche GI brands like MYTESI, the largest swing factor is gross-to-net (rebates, discounts, chargebacks, and patient assistance). Even with stable demand, gross-to-net can move sharply with contracting strategy and payer mix.

Practical payers-and-channel mechanics typically observed for GI specialty/niche products:

• High rebate dependency if the product is placed through preferred arrangements with managed care.
• Shorter coverage cycles where formularies revisit status annually.
• Patient assistance usage that rises when list price is higher and copays increase.
• Pharmacy benefit manager (PBM) contracting that can delay adoption until a plan moves from non-covered to covered.

MYTESI’s financial trajectory is therefore tied to whether the company improves:

• net pricing after rebates and discounts,
• persistence (repeat scripts rather than one-time use),
• and channel fill stability (reducing inventory swings that distort revenue timing).

---

Where does MYTESI sit in the GI treatment landscape?

How does MYTESI compete against alternatives?

The GI diarrhea space is crowded with low-cost symptomatic options and other branded therapies. MYTESI’s commercial relevance hinges on payer willingness to cover a branded, plant-derived agent when cheaper symptom controls exist.

Competition dimensions:

• Cost: payers often steer toward lower-cost agents when evidence and guideline positioning does not force branded uptake.
• Guideline embedding: where MYTESI does not anchor in major guidelines, prescriber ordering depends more on experience and specialty familiarity.
• Perceived differentiation: differentiated symptom outcomes can drive retention, but evidence must be repeatedly reinforced with real-world and trial data.

---

What is MYTESI’s financial trajectory: growth, profitability, and cash burn?

What revenue pattern should be expected for MYTESI?

MYTESI’s revenue trajectory in markets like the US is usually non-linear, reflecting adoption and payer access rather than steady linear scaling. For a niche GI asset, the common pattern is:

1. launch period ramp in covered markets,
2. periodic step-ups tied to payer contracting and evidence updates,
3. plateaus when payer coverage is stable and prescriber base saturates,
4. downside risks if gross-to-net rises faster than script volume.

Revenue growth, when it occurs, is typically driven by:

• incremental formulary placements,
• improved patient adherence,
• and expanded prescribing by gastroenterology centers.

What drives the profit and loss profile?

For MYTESI, profitability is constrained by commercialization costs and the economics of a smaller sales base:

• Operating expense burden: field sales costs, medical affairs, market access, and overhead.
• Manufacturing and inventory: unit economics depend on production scale and sell-through.
• Gross-to-net drag: net revenue can underperform topline script growth when contracting becomes more aggressive or when patient assistance expands.

The company’s financial trajectory therefore tends to follow a “cash flow first” logic: manage burn while sustaining commercialization and funding pipeline programs.

---

What do market events and regulatory timing mean for MYTESI?

How do label changes and evidence updates affect demand?

Market dynamics for MYTESI are sensitive to any shift that changes:

• prescriber willingness to try the drug earlier in the treatment pathway,
• payer confidence that the product delivers meaningful outcomes,
• and patient access behavior.

Demand uplift typically comes from:

• clearer positioning in guidelines,
• expanded eligible populations in labeling,
• post-marketing evidence or data that strengthens payer utilization.

Conversely, if evidence does not expand the eligible patient segment or if competing therapies gain stronger evidence, MYTESI’s growth can flatten and net pricing can erode.

---

Who controls MYTESI’s commercial scale?

What leverage does Napo Pharmaceuticals have in scaling MYTESI?

For specialty/niche brands, commercial scale depends on:

• depth and reach of GI-focused sales coverage,
• market access intensity (Payer contracting and coverage education),
• and medical affairs support that reduces utilization barriers.

The financial trajectory will be most favorable when incremental selling expense produces proportional net revenue. If script growth requires disproportionate selling spend or payer contracting concessions, operating leverage does not materialize.

---

What investment and R&D implications follow from MYTESI’s market dynamics?

How should business stakeholders interpret MYTESI’s trajectory?

For an asset with a restricted niche, the key underwriting question is not whether MYTESI exists in the market, but whether:

• net revenue is stable despite gross-to-net and payer pressure,
• utilization is persistent (repeat prescribing),
• and operating expenses stay aligned with the size of the addressable segment.

If the product cannot expand addressable demand, growth must come from share gain within a constrained segment, which typically forces higher contracting intensity. That shifts the company’s financial trajectory from “volume-driven growth” to “margin-managed survival.”

---

Key Takeaways

• MYTESI’s market dynamics are defined by niche GI adoption, payer access, and low switching friction among symptomatic diarrhea therapies.
• Financial trajectory depends primarily on gross-to-net discipline, persistence of use, and whether commercialization costs create proportional net revenue.
• Sustained growth requires expanding eligible segments or payer coverage depth; otherwise, revenue tends to plateau and profitability remains constrained by operating expense scale.
• Commercial scale leverage comes from market access execution and gastroenterology-focused sales and medical support, not broad primary-care penetration.
• Business risk is dominated by payer contracting concessions and inventory timing effects, not by a blockbuster-like demand ramp.

---

FAQs

1) What makes MYTESI’s demand structure different from larger GI brands?

Indication specificity and payer coverage intensity. Script volume is concentrated in GI practices and is sensitive to formulary status.

2) What is the biggest financial swing factor for MYTESI?

Gross-to-net economics, driven by rebates, discounts, chargebacks, and patient assistance mix.

3) Why can MYTESI’s growth plateau even if prescribers like the product?

Payer utilization rules and coverage edits can limit repeat prescribing, capping the addressable demand even with stable clinician preference.

4) What commercialization activities most affect MYTESI’s net sales trajectory?

Market access contracting, prior authorization reduction workflows, and GI-focused field execution that improves persistence.

5) What does MYTESI’s trajectory imply for underwriting future GI niche products?

Investors should underwrite around net revenue sustainability and operating leverage, not just topline script expectations.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). MYTESI (crofelemer) prescribing information. https://www.accessdata.fda.gov/